Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
You may also be interested in...
Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.
Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.